BioScience Health Innovations annual gross margin
2023
2024
2025
BioScience Health Innovations's gross margin was 56.97% for fiscal 2025.
View full BioScience Health Innovations company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 56.97% | −13.98 pp |
| 2024 | 2024-12-31 | 70.94% | −10.12 pp |
| 2023 | 2023-12-31 | 81.06% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 63.63% | +2.50 pp |
| Q1 2026 | 2026-03-31 | 64.66% | −8.37 pp |
| Q4 2025 | 2025-12-31 | 36.36% | −19.19 pp |
| Q3 2025 | 2025-09-30 | 61.71% | −12.42 pp |
| Q2 2025 | 2025-06-30 | 61.14% | −19.65 pp |
| Q1 2025 | 2025-03-31 | 73.03% | −11.54 pp |
| Q4 2024 | 2024-12-31 | 55.56% | −22.34 pp |
| Q3 2024 | 2024-09-30 | 74.13% | −9.31 pp |
| Q2 2024 | 2024-06-30 | 80.79% | −5.53 pp |
| Q1 2024 | 2024-03-31 | 84.57% | −0.75 pp |
| Q4 2023 | 2023-12-31 | 77.89% | −5.22 pp |
| Q3 2023 · Sep 30 | 2023-09-30 | 83.44% | −4.36 pp |
| Q3 2023 · Jun 30 | 2023-06-30 | 86.33% | +9.62 pp |
| Q2 2023 · Mar 31 | 2023-03-31 | 85.32% | — |
| Q3 2023 · Sep 30 | 2022-09-30 | 83.11% | — |
| Q3 2022 · Jun 30 | 2022-06-30 | 87.80% | — |
| Q2 2022 · Mar 31 | 2022-03-31 | 76.70% | — |
Across the available reported history, BioScience Health Innovations's gross margin decreased from 70.94% to 56.97%, a change of −13.98 percentage points. The latest reported quarter, Q2 2026, shows 63.63%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioScience Health Innovations filings at SEC.gov ↗